Compare Abeona Therapeutics Inc (ABEO) vs Gitlab Inc (GTLB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Gitlab Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Gitlab Inc trades at $31.88 (market cap $5.50B). The key difference: Gitlab Inc is far larger — about 14.7× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Gitlab Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | GTLB | |
|---|---|---|
Market Cap | $373.32M | $5.50B |
Sector | Health | Technology |
52-Week High | $7.23 | $51.04 |
52-Week Low | $4.17 | $19.42 |
Enterprise Value | $228.22M | $4.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
GitLab (GTLB) trades at $32.59, up 1.62% today, with a bullish technical signal and recent earnings beats. The stock shows strong revenue growth, reaching $759 million in 2025, but remains unprofitable with a negative net margin. Analyst sentiment is mixed, with a consensus price target of $31.86, while recent news highlights its leadership in DevSecOps and AI-driven software development.
Outlook: GitLab's growth trajectory and strategic position in AI and DevSecOps present upside potential, but profitability concerns and high valuation ratios pose risks. Investors should weigh strong revenue expansion against ongoing losses and competitive pressures in the technology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →
